{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Martin D"],"funding":["Else-Kröner-Research Foundation"],"pubmed_abstract":["Anal squamous cell carcinoma (ASCC) is associated with immunosuppression and infection with human papillomavirus (HPV). Response to standard chemoradiotherapy (CRT) varies considerably. A comprehensive molecular characterization of CRT resistance is lacking, and little is known about the interplay between tumor immune contexture, host immunity, and immunosuppressive and/or immune activating effects of CRT. Patients with localized ASCC, treated with CRT at three different sites of the German Cancer Consortium (DKTK) were included. Patient cohorts for molecular analysis included baseline formalin fixed paraffin embedded biopsies for immunohistochemistry (n = 130), baseline RNA sequencing (n = 98), peripheral blood immune profiling (n = 47), and serum cytokine measurement (n = 35). Gene set e"],"journal":["NPJ precision oncology"],"pagination":["93"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11039690"],"repository":["biostudies-literature"],"pubmed_title":["Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma."],"pmcid":["PMC11039690"],"pubmed_authors":["Looso M","Hehlgans S","Fries L","Zips D","Rodel C","Diefenhardt M","Gani C","Fleischmann M","Martin D","Rodel F","Tinhofer I","Fokas E","Ziegler PK","Kalinauskaite G"],"additional_accession":[]},"is_claimable":false,"name":"Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma.","description":"Anal squamous cell carcinoma (ASCC) is associated with immunosuppression and infection with human papillomavirus (HPV). Response to standard chemoradiotherapy (CRT) varies considerably. A comprehensive molecular characterization of CRT resistance is lacking, and little is known about the interplay between tumor immune contexture, host immunity, and immunosuppressive and/or immune activating effects of CRT. Patients with localized ASCC, treated with CRT at three different sites of the German Cancer Consortium (DKTK) were included. Patient cohorts for molecular analysis included baseline formalin fixed paraffin embedded biopsies for immunohistochemistry (n = 130), baseline RNA sequencing (n = 98), peripheral blood immune profiling (n = 47), and serum cytokine measurement (n = 35). Gene set e","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T09:18:03.238Z","creation":"2026-04-08T11:08:05.721Z"},"accession":"S-EPMC11039690","cross_references":{"pubmed":["38653773"],"doi":["10.1038/s41698-024-00585-y"]}}